Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Update

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 343,900 shares, an increase of 46.0% from the March 15th total of 235,600 shares. Approximately 1.6% of the company's stock are sold short. Based on an average trading volume of 287,400 shares, the days-to-cover ratio is presently 1.2 days.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Baader Bank Aktiengesellschaft purchased a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $373,000. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals in the third quarter valued at about $90,000. Geode Capital Management LLC boosted its holdings in Eton Pharmaceuticals by 13.5% during the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after buying an additional 32,365 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Eton Pharmaceuticals in the fourth quarter valued at about $147,000. Finally, Anchor Capital Advisors LLC acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at approximately $805,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Stock Up 4.3 %

Shares of Eton Pharmaceuticals stock traded up $0.64 during mid-day trading on Wednesday, hitting $15.68. The stock had a trading volume of 304,442 shares, compared to its average volume of 285,935. The firm has a market cap of $420.51 million, a P/E ratio of -71.27 and a beta of 1.34. Eton Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $18.41. The firm has a 50-day moving average of $14.10 and a two-hundred day moving average of $12.82.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The company had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Sell-side analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

Wall Street Analyst Weigh In

ETON has been the topic of a number of recent research reports. B. Riley reaffirmed a "buy" rating and set a $24.00 price objective (up previously from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Craig Hallum boosted their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.